SLC6A11 and Alzheimer disease: In comparison, GAT3/4 levels also increased in AD patients compared to the expression levels in control human tissue by, 226.13 ± 58.09% and 630.86 ± 79.33% in CA1 and DG, respectively (n = 5, **p ≤ .01), (Figure 1J).